MDN-001
/ Mednovo
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 07, 2026
MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Suzhou Mednovo Yi Medical Technology Co., Ltd.
New P1 trial • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1